Press Release **For Immediate Dissemination**

Crofelemer, a first-in-class anti-diarrhoeal drug, enters Pivotal trials for Adult Acute Diarrhoea including Cholera

- This pivotal study in over 700 patients with adult acute diarrhoea will also include patients with Cholera
- Dosing in patients has commenced.
- Glenmark has exclusive Crofelemer rights for diarrhoea indications in nearly 140 countries including India and is the sole API supplier globally for Crofelemer (ex-China)
- For HIV associated diarrhoea, Glenmark anticipates filings to begin in ROW markets in FY 2012-13 based on the availability of the complete regulatory dossier data.

December 28, 2011: Glenmark Pharmaceuticals today announced that they have obtained the DCGI(India) approval for conduct of the pivotal study of "Crofelemer" in Acute Watery Diarrhoea patients. Post approval from the DCGI, dosing in patients has also commenced. This is a randomized, double blinded, placebo controlled, parallel Group, three arm, multicenter and multinational pivotal study that is being carried out to assess the Efficacy and Safety of two dosage regimens of Crofelemer Tablets in the Treatment of Moderate to Severe Acute Watery Diarrhoea in Adult Patients including cholera. **This Phase III study will be done at leading centres in India and Bangladesh.**

"We are delighted to commence Phase III trials for Crofelemer in adult acute diarrhoea. Adult diarrhoea is a big concern around the world especially in emerging markets and globally millions of patients suffer from diarrhoea every year" **said Mr. Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Limited.**

Glenmark remains committed to the development of Crofelemer across various diarrhoea indications that it holds exclusive rights.

C-FORWARD STUDY

A phase III human clinical trial in patients with Moderate to Severe Acute Watery Diarrhoea has been planned at leading medical centers in India and

Bangladesh. Glenmark has received approval from DCGI for conduct of study and patient enrolment has been initiated and dosing has commenced. This study is expected to be completed by the fourth quarter of CY 2012. The primary objective is to assess the efficacy of Crofelemer versus Placebo in the treatment of Moderate to Severe Acute Watery Diarrhoea in Adult Patients as defined by stool output relative to bodyweight. This has a direct impact on reducing the dehydration which is the major cause of morbidity and mortality in diarrhoeal diseases mainly cholera. The total number of patients for this study will be over 700

Glenmark Pharmaceuticals has an exclusive license from Napo Pharmaceuticals, Inc. to distribute and commercialise Crofelemer in 140 emerging countries (rest of world, or "ROW" territories) including India for indications related to HIV, use in acute adult and pediatric diarrhoea. Crofelemer is a novel, first-in-class anti-diarrhoeal agent that has a physiological and different mechanism of action from traditional anti-diarrhoeal agents. Besides its potential efficacious role in multiple diarrhoeal indications, Crofelemer controls diarrhoea with no drug-drug interactions, minimal systemic adsorption and, unlike current anti-diarrhoeals, no serious side effects.

Although Napo has purported to terminate Glenmark's license, Glenmark vehemently denies that Napo has any basis for terminating its license and is seeking a declaration from an arbitration panel that Napo's claims of breach are unfounded.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has twelve manufacturing facilities in four countries and has five R&D centres.

####

For further information, please contact:
Jason D'Souza/ Rajdeep Barooah
Glenmark, Mumbai, India
Tel: [+91 22] 40189919/40189984
Email : media@glenmarkpharma.com